The study of CD30-CAR T in cHL began in the late 1990s, but the clinical application has been plagued by suboptimal response rate and duration of response, albeit generally good tolerance Based on pre-clinical data of a CD30-CAR T construct using a mouse-derived anti-CD30 monoclonal antibody as scFv, Ramos, et al., conducted a phase 1 clinical trial enrolling nine patients with heavily pretreated Epstein-Barr virus (EBV)-, CD30+ lymphoma, including seven with cHL (NCT01316146) (147, 148). Here, TNFRSF8 is linked to lymphoma.